Immunovant (NASDAQ:IMVT – Free Report) had its price objective decreased by Bank of America from $38.00 to $33.00 in a ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The company plans to use results from its Phase III ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going ...

In this article, we will discuss the 10 Best Stocks to Buy According to Billionaire David Einhorn. David Einhorn is a highly ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

Among domestic companies, HANALL BIOPHARMA is developing ‘batoclimab’ as a treatment for various autoimmune diseases in partnership with U.S. partner Immunovant. The company announced this ...